X

Trial Profile

Enhanced Histone H3.3-K27M Neoantigen Vaccine Therapy Against Diffuse Intrinsic Pontine Glioma (ENACTING)- a Phase I Clinical Trial

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 15 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Histone H3.3-K27M Neoantigen Vaccine - TCRCure Biopharma (Primary)
Indications Diffuse intrinsic pontine glioma
Focus Adverse reactions; Therapeutic Use
Acronyms ENACTING

Most Recent Events

11 Nov 2024 Status changed from recruiting to discontinued as the interim analysis has demonstrated the safety of the treatment and indicated a moderate survival benefit for patients. Essentially, the primary objectives have been achieved
25 Jul 2023 Planned End Date changed from 1 Apr 2024 to 1 Dec 2024.
25 Jul 2023 Planned primary completion date changed from 31 Mar 2023 to 31 Mar 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com